Skip to content
value.today

Coherus Oncology, Inc.

CHRS
No market cap data
Compare
World rank
—
no current market cap
Revenue
$42 M
For year ending December-2025
Net income
$168 M
398.4% margin
SEC filing
Employees
—

Coherus Oncology, Inc. in brief

Coherus Oncology, Inc. is a listed company in the Biotechnology industry, based in Redwood City, California, USA. In the year to December 2025 it had sales of $42 M and a net profit of $168 M. Its largest product and service lines by sales in 2025 were Toripalimab (97%). Its shares trade under the symbol CHRS (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Coherus Oncology, Inc.

We are a fully integrated commercial-stage innovative oncology company with an approved next-generation programmed death receptor-1 inhibitor, LOQTORZI® (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, head and neck, colorectal and other cancers. Our strategy is to grow sales of LOQTORZI in nasopharyngeal carcinoma and advance the development of new indications for LOQTORZI in combination with both our pipeline candidates as well as our partners, driving sales multiples and synergies from proprietary combinations. On May 29, 2025, we changed our corporate name from “Coherus BioSciences, Inc.” to “Coherus Oncology, Inc.” to better align with our exclusive focus on proprietary innovative immuno-oncology medicines following the completion of the recent divestitures of our biosimilar businesses.

From the company's annual report filed with the US SEC: read the report

Coherus Oncology, Inc. timeline

6 events, 2011–2025
  1. 2011
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2012
  4. ✎
    Renamed Coherus BioSciences, Inc.
    Formerly BioGenerics, Inc..
  5. 2014
  6. 🔔
    Initial public offering as Coherus BioSciences, Inc.
    Final prospectus filed with the SEC on 6 November 2014; shares registered for exchange trading on 3 November 2014.
  7. 2020
  8. 💰
    Record revenue of $476 million
    FY2020, the highest of the 7 years on record.
  9. 2025
  10. 💰
    Record net income of $168 million
    FY2025, the highest profit of the 4 years on record.
  11. ✎
    Renamed Coherus Oncology, Inc.
    Formerly Coherus BioSciences, Inc..

Events of Coherus Oncology, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

Not enough history yet.

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
—
Price / book
—
Free cash flow yield
—
Net margin (TTM)
-253.4%
Operating margin
-429.5%
Return on equity
-222.8%
Liabilities / assets
76.4%
Net debt
$-104M
Revenue growth
+59.8%
R&D / revenue
258.2%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $-209M—FY18Fiscal year ending Dec 2019: revenue $356M, net income $90M$356MFY19Fiscal year ending Dec 2020: revenue $476M, net income $132M$476MFY20Fiscal year ending Dec 2021: revenue $327M, net income $-287M$327MFY21Fiscal year ending Dec 2022: revenue $211M, net income $-292M$211MFY22Fiscal year ending Dec 2023: revenue $1M, net income $-238M$1MFY23Fiscal year ending Dec 2024: revenue $26M, net income $29M$26MFY24Fiscal year ending Dec 2025: revenue $42M, net income $168M$42MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$42M+59.8%$-181M$168M398.4%
Dec 2024$26M+2063.1%$-200M$29M108.0%
Dec 2023$1M-99.4%$-216M$-238M-19499.2%
Dec 2022$211M-35.4%$-257M$-292M-138.2%
Dec 2021$327M-31.4%$-264M$-287M-87.9%
Dec 2020$476M+33.6%$156M$132M27.8%
Dec 2019$356M—$108M$90M25.2%
Dec 2018——$-204M$-209M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-139M——$1.43—
Dec 2024$-20M——$0.25—
Dec 2023$-175M$0M$-175M$-2.53—
Dec 2022$-241M$2M$-243M$-3.76—
Dec 2021$-37M$1M$-39M$-3.81—
Dec 2020$154M$7M$147M$1.62—
Dec 2019$28M$2M$27M$1.23—
Dec 2018$-159M$1M$-160M$-3.22—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$54M
Net income, trailing 12 months
$-136M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $8M, net income $-51M$8MDec ’24Three months to Mar 2025: revenue $8M, net income $-57M$8MMar ’25Three months to Jun 2025: revenue $10M, net income $298M$10MJun ’25Three months to Sep 2025: revenue $12M, net income $-36M$12MSep ’25Three months to Dec 2025 (from the annual report): revenue $13M, net income $-38M$13MDec ’25Three months to Mar 2026: revenue $12M, net income $-38M$12MMar ’26Three months to Jun 2026: revenue $14M, net income $-21M$14MJun ’26Three months to Sep 2026: revenue $14M, net income $-39M$14MSep ’26

Latest quarter to Sep 2026: revenue $14M (+23.3% on a year earlier), net income $-39M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Coherus Oncology, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$42 M
Operating income
$-181 M
Net income
$168 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$258 M
Total liabilities
$197 M
Total equity
$61 M

As of December-2025

Top 100 institutional investors in Coherus Oncology, Inc.#

As of Sep 30, 2026
136 institutions held 66.3 M shares (about 42.9% of the shares outstanding) on Sep 30, 2026. The ten largest hold 31.3%. Source: SEC Form 13F filings, filed through Nov 18, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Coherus Oncology, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Timothy G. Youngquist 2020 Irrevocable Trust13,050,6230 (0.00%)8.44%$16 MOct 13, 2026
2BlackRock, Inc.11,742,006-261,310 (-2.18%)7.60%$14 MNov 13, 2026
3Vanguard Capital Management LLC5,598,339-351,151 (-5.90%)3.62%$7 MNov 13, 2026
4Samsara Biocapital, LLC3,383,565-45,006 (-1.31%)2.19%$4 MNov 16, 2026
5Geode Capital Management, LLC3,098,735-586,832 (-15.92%)2.01%$4 MNov 6, 2026
6Kohlberg Kravis Roberts & Co. L.P.3,036,0760 (0.00%)1.96%$4 MNov 13, 2026
7State Street Corp2,426,779+44,474 (+1.87%)1.57%$3 MNov 12, 2026
8CM Management, LLC2,100,0000 (0.00%)1.36%$3 MNov 12, 2026
9Goldman Sachs Group Inc1,995,469+1,393,394 (+231.43%)1.29%$2 MNov 16, 2026
10C WorldWide Group Holding A/S1,928,4640 (0.00%)1.25%$2 MNov 4, 2026
11ADAR1 Capital Management, LLC1,886,346+1,875,980 (+18097.43%)1.22%$2 MNov 16, 2026
12Hudson Bay Capital Management LP1,733,000+40,000 (+2.36%)1.12%$2 MNov 13, 2026
13Charles Schwab Investment Management Inc1,218,004-10,065 (-0.82%)0.79%$1 MNov 16, 2026
14UBS Group AG1,028,832+268,474 (+35.31%)0.67%$1 MNov 10, 2026
15Northern Trust Corp1,018,742-110,728 (-9.80%)0.66%$1 MNov 16, 2026
16Renaissance Technologies LLC941,828+378,772 (+67.27%)0.61%$1 MNov 12, 2026
17Panagora Asset Management Inc907,876-229,449 (-20.17%)0.59%$1 MNov 12, 2026
18Nomura Asset Management International Inc.900,000+1 (0.00%)0.58%$1 MNov 16, 2026
19Vanguard Fiduciary Trust Co886,320-129,671 (-12.76%)0.57%$1 MNov 13, 2026
20Vanguard Portfolio Management LLC833,694-49,760 (-5.63%)0.54%$1 MNov 13, 2026
21Bank Of America Corp /de/424,202+121,674 (+40.22%)0.27%$1 MNov 16, 2026
22Invesco Ltd.371,021+17,099 (+4.83%)0.24%$0 MNov 12, 2026
23Bank of New York Mellon Corp331,077+11,390 (+3.56%)0.21%$0 MNov 5, 2026
24Citadel Advisors LLC282,191+240,080 (+570.11%)0.18%$0 MNov 16, 2026
25Nuveen, LLC279,842+29,093 (+11.60%)0.18%$0 MNov 10, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Coherus Oncology, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Morgan Stanley277,922+47,174 (+20.44%)0.18%$0 MNov 13, 2026
27Barclays PLC230,929+29,786 (+14.81%)0.15%$0 MNov 6, 2026
28Alliancebernstein L.P.221,9000 (0.00%)0.14%$0 MNov 16, 2026
29AQR Capital Management LLC218,597-1,111,604 (-83.57%)0.14%$0 MNov 16, 2026
30Millennium Management LLC196,342+175,593 (+846.27%)0.13%$0 MNov 16, 2026
31Bridgeway Capital Management, LLC175,000-216,000 (-55.24%)0.11%$0 MNov 16, 2026
32Empowered Funds, LLC175,000New0.11%$0 MNov 13, 2026
33DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main159,9900 (0.00%)0.10%$0 MNov 16, 2026
34Acadian Asset Management LLC156,198+6,971 (+4.67%)0.10%$0 MNov 9, 2026
35Citigroup Inc154,112+89,770 (+139.52%)0.10%$0 MNov 4, 2026
36Rhumbline Advisers146,206+3,845 (+2.70%)0.09%$0 MNov 10, 2026
37Tyche Wealth Partners LLC144,202-57,000 (-28.33%)0.09%$0 MNov 10, 2026
38Summit Financial, LLC114,834-27 (-0.02%)0.07%$0 MNov 12, 2026
39Deutsche Bank AG\111,614-16,007 (-12.54%)0.07%$0 MNov 6, 2026
40Price T Rowe Associates Inc /MD/108,7500 (0.00%)0.07%$0 MNov 16, 2026
41Shay Capital LLC105,3260 (0.00%)0.07%$0 MNov 16, 2026
42Corient Private Wealth LP100,005+5 (+0.01%)0.06%$0 MNov 16, 2026
43HSBC Holdings PLC91,8950 (0.00%)0.06%$0 MNov 16, 2026
44XTX Topco Ltd85,247-38,250 (-30.97%)0.06%$0 MNov 16, 2026
45SEI Investments Co76,6290 (0.00%)0.05%$0 MNov 10, 2026
46PVG Asset Management Corp74,160-59,075 (-44.34%)0.05%$0 MOct 19, 2026
47SteelPeak Wealth, LLC71,408+2,408 (+3.49%)0.05%$0 MOct 16, 2026
48Jpmorgan Chase & Co69,361+3,295 (+4.99%)0.04%$0 MNov 12, 2026
49Strs Ohio68,200-327,400 (-82.76%)0.04%$0 MOct 30, 2026
50Envestnet Asset Management Inc63,823-77,047 (-54.69%)0.04%$0 MNov 16, 2026
51MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.63,369+3,183 (+5.29%)0.04%$0 MNov 16, 2026
52HRT Financial LP61,058New0.04%$0 MNov 13, 2026
53Susquehanna International Group, LLP58,924-50,703 (-46.25%)0.04%$0 MNov 16, 2026
54Vanguard Global Advisers, LLC58,421+612 (+1.06%)0.04%$0 MNov 13, 2026
55Canton Hathaway, LLC58,2300 (0.00%)0.04%$0 MOct 23, 2026
56Russell Investments Group, Ltd.50,6130 (0.00%)0.03%$0 MNov 6, 2026
57LPL Financial LLC45,967-2,200 (-4.57%)0.03%$0 MNov 6, 2026
58International Assets Investment Management, LLC45,501+2,543 (+5.92%)0.03%$0 MNov 2, 2026
59Quadrature Capital Ltd43,371New0.03%$0 MNov 13, 2026
60Cambridge Investment Research Advisors, Inc.42,186-62,566 (-59.73%)0.03%$0 MNov 2, 2026
61BNP Paribas Financial Markets37,754+11,321 (+42.83%)0.02%$0 MNov 12, 2026
62Manufacturers Life Insurance Company, The37,474-1,146 (-2.97%)0.02%$0 MNov 13, 2026
63Vanguard Personalized Indexing Management, LLC34,228+1,078 (+3.25%)0.02%$0 MNov 16, 2026
64Cetera Investment Advisers33,363+1,436 (+4.50%)0.02%$0 MNov 13, 2026
65Boothbay Fund Management, LLC32,292+17,005 (+111.24%)0.02%$0 MNov 16, 2026
66Leonteq Securities AG30,746New0.02%$0 MOct 29, 2026
67Wells Fargo & Company/mn29,488-83,415 (-73.88%)0.02%$0 MNov 16, 2026
68Police & Firemen's Retirement System of New Jersey28,2300 (0.00%)0.02%$0 MNov 9, 2026
69China Universal Asset Management Co., Ltd.28,190+3,641 (+14.83%)0.02%$0 MOct 28, 2026
70Voya Investment Management LLC27,6520 (0.00%)0.02%$0 MNov 10, 2026
71Raymond James Financial Inc27,102New0.02%$0 MNov 12, 2026
72Two Sigma Securities, LLC26,613+16,570 (+164.99%)0.02%$0 MNov 16, 2026
73Ieq Capital, LLC25,541-136,812 (-84.27%)0.02%$0 MNov 10, 2026
74Brevan Howard Capital Management LP25,371New0.02%$0 MNov 16, 2026
75Centiva Capital, LP22,141New0.01%$0 MNov 13, 2026
76Atria Investments, Inc21,827-4,599 (-17.40%)0.01%$0 MOct 15, 2026
77Prudential Financial Inc20,8350 (0.00%)0.01%$0 MNov 16, 2026
78ProShare Advisors LLC20,700-1,472 (-6.64%)0.01%$0 MOct 29, 2026
79New York State Common Retirement Fund20,5930 (0.00%)0.01%$0 MNov 17, 2026
80Medallion Wealth Advisors, LLC20,000+5,000 (+33.33%)0.01%$0 MNov 13, 2026
81Wealth Enhancement Advisory Services, LLC19,322-42,933 (-68.96%)0.01%$0 MOct 13, 2026
82Cerity Partners LLC19,262-55,345 (-74.18%)0.01%$0 MNov 13, 2026
83Stratos Wealth Partners, LTD.16,1310 (0.00%)0.01%$0 MNov 13, 2026
84Bronte Capital Management Pty Ltd.15,2620 (0.00%)0.01%$0 MNov 12, 2026
85Dimensional Fund Advisors LP15,055-20,342 (-57.47%)0.01%$0 MNov 4, 2026
86Providence Wealth Advisors, LLC15,0000 (0.00%)0.01%$0 MOct 29, 2026
87Kingsbury Capital Investment Advisors LLC14,545+2,149 (+17.34%)0.01%$0 MOct 20, 2026
88Wealth Group, Ltd.14,195New0.01%$0 MOct 30, 2026
89Jane Street Group, LLC13,528-25,135 (-65.01%)0.01%$0 MNov 12, 2026
90StoneX Group Inc.13,454New0.01%$0 MNov 3, 2026
91Victory Capital Management Inc13,184-242 (-1.80%)0.01%$0 MNov 10, 2026
92Vontobel Holding Ltd.13,066New0.01%$0 MOct 16, 2026
93Legal & General Group Plc12,7140 (0.00%)0.01%$0 MNov 16, 2026
94CIBC Bancorp USA Inc.12,603New0.01%$0 MNov 13, 2026
95Xponance LLC12,218-216 (-1.74%)0.01%$0 MNov 3, 2026
96Endowment Wealth Management, Inc.11,5210 (0.00%)0.01%$0 MNov 3, 2026
97EFG International AG11,5000 (0.00%)0.01%$0 MNov 16, 2026
98TRB Wealth Management, LLC11,3260 (0.00%)0.01%$0 MNov 16, 2026
99Group One Trading LLC11,323-9,523 (-45.68%)0.01%$0 MNov 10, 2026
100Neuberger Berman Group LLC10,605-3,783 (-26.29%)0.01%$0 MNov 13, 2026

All 136 institutional investors, with who bought and sold →

Mutual funds holding Coherus Oncology, Inc.#

96 funds hold shares worth $29 M (about 13.1% of the company). Since their previous reports 51 added shares and 16 sold, buying $4 M net.
Mutual funds holding Coherus Oncology, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.3.95 M$6 M2.6%<0.01%+8.9%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors3.22 M$5 M2.1%<0.01%+29%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.1.86 M$3 M1.2%<0.01%+10%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC1.42 M$2 M0.92%<0.01%+40%Jul 31, 2026
🇺🇸 BlackRock Advantage Small Cap Core FundBlackRock Advisors, LLC927,830$1 M0.60%0.03%−1.2%May 29, 2026
🇺🇸 Nomura Healthcare FundDelaware Management Company900,000$1 M0.58%0.17%no changeJun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC783,155$1 M0.51%<0.01%+22%May 31, 2026
🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc.709,098$1 M0.46%<0.01%+20%May 31, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors741,539$1 M0.48%<0.01%+17%Jun 30, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.535,033$1 M0.35%<0.01%+2.1%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors438,059$1 M0.28%0.04%+68%Jun 30, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors436,778$1 M0.28%<0.01%+71%Jun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.318,186$0 M0.21%<0.01%+36%Jul 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC267,846$0 M0.17%<0.01%+12%May 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC274,247$0 M0.18%<0.01%+39%Jun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC227,152$0 M0.15%<0.01%+31%May 31, 2026
🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC210,439$0 M0.14%0.01%−9.6%Jul 31, 2026
🇺🇸 BlackRock Advantage Small Cap Growth FundBlackRock Funds203,071$0 M0.13%0.03%+30%Jun 30, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC200,000$0 M0.13%0.19%+33%Jun 30, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC174,120$0 M0.11%<0.01%+30%Jul 31, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC142,268$0 M0.09%<0.01%+48%Jun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC127,980$0 M0.08%<0.01%+6.9%Jun 30, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC117,771$0 M0.08%<0.01%+34%Jun 30, 2026
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.1.71 M$0 M—<0.01%no changeJun 30, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.109,420$0 M0.07%<0.01%no changeJul 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC91,739$0 M0.06%<0.01%no changeMay 31, 2026
🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc.91,696$0 M0.06%<0.01%+1.6%May 31, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC83,840$0 M0.05%<0.01%−6.5%Jul 31, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC79,950$0 M0.05%<0.01%no changeJun 30, 2026
🇺🇸 AQR Small Cap Multi-Style FundAQR CAPITAL MANAGEMENT, LLC78,726$0 M0.05%0.03%−18%Jun 30, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.76,969$0 M0.05%<0.01%+31%Jun 30, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation76,805$0 M0.05%<0.01%no changeJun 30, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.68,166$0 M0.04%<0.01%+26%Jun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.67,253$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.65,031$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC62,442$0 M0.04%<0.01%+39%Jul 31, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC61,963$0 M0.04%<0.01%+19%Jul 31, 2026
🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc.54,650$0 M0.04%<0.01%+4.6%May 31, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company42,500$0 M0.03%<0.01%no changeMay 31, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC46,222$0 M0.03%<0.01%+26%Jun 30, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC45,358$0 M0.03%<0.01%+68%Jun 30, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC44,576$0 M0.03%<0.01%+30%Jun 30, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC43,837$0 M0.03%<0.01%+73%Jun 30, 2026
🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors43,427$0 M0.03%<0.01%−24%Jun 30, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.42,517$0 M0.03%<0.01%+12%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.579,706$0 M—<0.01%no changeJun 30, 2026
🇺🇸 Goldman Sachs Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P.37,384$0 M0.02%<0.01%no changeJul 31, 2026
🇺🇸 AQR Small Cap Momentum Style FundAQR CAPITAL MANAGEMENT, LLC30,915$0 M0.02%0.03%—Mar 31, 2026
🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc.32,543$0 M0.02%<0.01%+3.0%May 31, 2026
🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC36,015$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 Clearwater Select Equity FundClearwater Management Co Inc.32,477$0 M0.02%<0.01%−32%Jun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC29,359$0 M0.02%0.02%+62%Jun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC29,001$0 M0.02%<0.01%+51%Jun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS28,077$0 M0.02%<0.01%+51%Jun 30, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC23,497$0 M0.02%<0.01%+4.6%Jul 31, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC22,239$0 M0.01%<0.01%no changeJul 31, 2026
🇺🇸 Goldman Sachs Variable Insurance Trust Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P.21,782$0 M0.01%0.01%no changeJun 30, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC21,016$0 M0.01%<0.01%+70%Jun 30, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.20,484$0 M0.01%<0.01%+34%Jun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.19,935$0 M0.01%<0.01%+93%Jun 30, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC17,535$0 M0.01%<0.01%+67%Jun 30, 2026
🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION14,800$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors16,634$0 M0.01%<0.01%−0.8%Jun 30, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust14,072$0 M<0.01%<0.01%−47%May 31, 2026
🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP15,055$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.13,426$0 M<0.01%<0.01%−4.9%Jul 31, 2026
🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC12,362$0 M<0.01%<0.01%+3.4%Jun 30, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC11,838$0 M<0.01%<0.01%−0.3%Jul 31, 2026
🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP11,365$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC10,821$0 M<0.01%<0.01%+45%Jun 30, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC10,117$0 M<0.01%<0.01%+57%Jun 30, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management9,819$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc.9,355$0 M<0.01%<0.01%−8.5%Jun 30, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS9,257$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP8,977$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC8,784$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.7,172$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC8,100$0 M<0.01%<0.01%+2.5%Jun 30, 2026
🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC6,777$0 M<0.01%<0.01%+180%Jul 31, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC6,711$0 M<0.01%<0.01%+5.7%Jun 30, 2026
🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC6,286$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC5,814$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC5,804$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC4,874$0 M<0.01%<0.01%+6.1%May 31, 2026
🇺🇸 Morgan Stanley Pathway Small-Mid Cap Equity ETFCONSULTING GROUP ADVISORY SERVICES LLC4,536$0 M<0.01%<0.01%−5.3%May 31, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC4,547$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC3,812$0 M<0.01%<0.01%−42%May 31, 2026
🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC3,853$0 M<0.01%<0.01%−41%May 31, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC3,989$0 M<0.01%<0.01%+13%Jul 31, 2026
🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS3,744$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC3,673$0 M<0.01%<0.01%+32%Jun 30, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC3,363$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC3,095$0 M<0.01%<0.01%−28%Jun 30, 2026
🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC2,921$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC2,752$0 M<0.01%<0.01%+17%Jun 30, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.2,726$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC1,851$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.24,474$0 M—<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.15,512$0 M—<0.01%no changeJun 30, 2026
🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC732$0 M<0.01%<0.01%+32%Jul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Coherus Oncology, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
25
since
-$451 K$0Nov 2023: bought $0 (0 trades), sold $451 K (1 trades)Nov 23May 2025: bought $0 (0 trades), sold $74 K (1 trades)May
Bought (open market)Sold (open market)Hover a month for the totals
Coherus Oncology, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Charles W. NewtonDirectorGrant or award+30,000——30,000Form 4
filed Rita A. KarachunDirectorGrant or award+30,000——30,000Form 4
filed Lee Nisley NewcomerDirectorGrant or award+30,000——30,000Form 4
filed Jill O'Donnell-TormeyDirectorGrant or award+30,000——30,000Form 4
filed Ali J. SatvatDirectorGrant or award+30,000——30,000Form 4
filed Mats WahlstromDirectorGrant or award+30,000——30,000Form 4
filed Michael Lee RyanDirectorGrant or award+30,000——30,000Form 4
filed Dennis M. LanfearPresident & CEO, DirectorGrant or award+375,000——1.05 MForm 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Coherus Oncology, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Buybacks, Q4 2014
$0M
Q4 2014

Stock splits: 1-for-1 split

Coherus Oncology, Inc. share buybacks by quarter
Buybacks, quarterFiscalSpent
Q4 2014Q4 2014$0M
Q3 2014Q3 2014$0M
Q2 2014Q2 2015$0M
Q1 2014Q1 2015$0M

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Coherus Oncology, Inc. scorecard#

Passes 5 of the 12 checks that could be worked out: strongest in growth (3 of 4), weakest in profitability (1 of 4). Fiscal year 2025.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth3 of 4
    • ✓Revenue grew in the newest year59.8%Revenue up 59.8% in fiscal 2025.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✓Earnings per share grew in the newest year1.43 vs 0.25Diluted EPS 1.43 in fiscal 2025 against 0.25 the year before (report's currency).
    • ✓Net income higher than five years earlier$168 M$168 M in fiscal 2025 against $132 M in 2020.
    • ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2025.
  • Profitability1 of 4
    • ✓Profitable in the newest year$168 MNet income $168 M in fiscal 2025.
    • ✗Profitable in each of the last five years2 of 5Profitable in 2 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-429.5%-429.5% against Biotechnology's median of -60.5% (243 companies).
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✗Operating margin wider than three years earlier-429.5%-429.5% in fiscal 2025 against -121.7% in 2022.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities1.5×Current ratio 1.47 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • ✗Operating income covers interest five times-20.1×Operating income -20.1 times interest in fiscal 2025.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year2.3%Diluted shares up 2.3% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Coherus Oncology, Inc.'s statements, beside the median of Biotechnology.

Coherus Oncology, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-429.5%-60.5%
Net margin398.4%-68.9%
Revenue growth59.8%15.8%

5of 8on the Piotroski tests of financial strength

  • Only -82% of net income arrived as cash from operations.
  • Operating income covers the interest bill only -20.1 times.

Coherus Oncology, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Coherus Oncology, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue4226r25721132747635601.6190
Cost of revenue148.7r15970583817———
Research and development10992r10919936314394110162254
Selling, general and administrative101125r192198170139137947152
General and administrative————————7152
Operating expenses——————248204234306
Total costs and expenses223226r460468590320248204——
Operating income−181−200r−203−257−264156108−204−232−116
Interest and finance income7.04.52.81.91.40.61.61.4——
Interest expense and finance costs9.011r41322321189.79.68.0
Other non-operating income (expense)7.07.6r5.53.8−0.30.62.64.73.4−3.9
Income before tax−183−215r−238−292−28713693−209−238—
Income tax00−0.4003.52.9000
Income from discontinued operations351244————————
Net income including minority interests16829−238−292−28713290−209−238−128
Minority interests' share of net income——————0−0.1−0.1−0.5
Net income attributable to shareholders16829−238−292−28713290−209−238−127
Earnings per share, basic1.430.25-2.53-3.76-3.811.851.29-3.22-4.48-3.04
Earnings per share, diluted1.430.25-2.53-3.76-3.811.621.23-3.22-4.48-3.04
Shares, weighted average (basic)11711594787571706553—
Shares, weighted average (diluted)117115r9478758373655342
Balance sheet
Cash and cash equivalents891261036441754117872r127125
Short-term investments83—15128——00——
Receivables181112611101231571420—1.9
Inventory3.24.2r633938449.81.7——
Other current assets6.210r1123115.65.00.10.13.0
Current assets20734247638160276734384145161
Property, plant and equipment1.32.6r5.18.87.8105.86.71311
Right-of-use (leased) assets3.04.55.95.78.210.0r110——
Goodwill——0.90.9r0.9r0.90.90.90.90.9
Other intangible assets2025725.9r3.6r2.62.62.62.62.6
Total assets25844963048167984240999163178
Accounts payable9.9283512161526151520
Current liabilities140283332139165146115332856
Lease liabilities (non-current)1.53.35.03.66.89.1100——
Total liabilities197581823618582561304138132159
Retained earnings−1,383−1,551−1,580−1,342−1,050−763−895−985−775−537
Shareholders' equity61−132−193−13798281105−3931r21
Minority interests————————−1.3−1.2
Total equity——————105−393119
Total liabilities and equity25844963048167984240999163178
Shares outstanding12111611279777370686046r
Cash-flow statement
Depreciation and amortization1.31.6r3.23.6r3.5r2.93.33.23.43.0
Share-based compensation17284351513834353327
Cash from operating activities−139−20−175−241−3715428−159−200−253
Capital expenditure——−0.3−2.0−1.3−7.2−1.8−0.8−4.6−6.5
Cash from investing activities375230145−167−138−14−13−1.2−4.4−6.5
Debt issued———241——————
Debt repaid—−260—−82——————
Shares issued—1.5——41—————
Cash from financing activities−274−18770545222489105207226
Exchange-rate effect on cash——————−0.30.5−0.1−0.4
Change in cash−372339−354−124364105−552.0−33
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Coherus Oncology, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Toripalimab$41 M97%
  • Other revenue$1 M3.2%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Executive pay at Coherus Oncology, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$2.7 M
Mr. Dennis Lanfear
Other top executives, average
$1.2 M
the CEO earned 2.3× this
$100 invested is now
$18
Coherus Oncology, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Mr. Dennis Lanfear$2.7 M$2.8 M$1.2 M$18
2024Chief executive$4.8 M$2.4 M$1.3 M$17
2023Chief executive$5.9 M$1.7 M$1.9 M$42

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Coherus Oncology, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Auditor changedFiling
  • Delisting noticeFiling

Delisting notice 1 · Auditor changed 1 · Acquisition or sale completed 1 · Directors and officers 2 · Material agreement 2 · Agreement ended 1 · New debt 1 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 10

Coherus Oncology, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Material agreementAgreement endedNew debt8-K
Results announced8-K
Auditor changed8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K
Results announced8-K
Results announced8-K
Delisting notice8-K
Shareholder vote8-K
Bylaws or fiscal year changed8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Acquisition or sale completed8-K
Material agreement8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026

Acquisitions and funding#

4 private funding rounds before listing

Private share sales · funding history

Private share sales of Coherus Oncology, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2017$7 MPrivate placement after listing$2 to $10 million1equitySEC
Sep 2015$10 MPrivate placement after listing$10 to $50 million1equitySEC
May 2014$56 MNo. 4$50 to $250 million35equitySEC
Jul 2013$28 MNo. 3$10 to $50 million6debt, optionsSEC
Jan 2012$46 MNo. 2$10 to $50 million23equitySEC
Jul 2011$13 MNo. 1$10 to $50 million15debt, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at Coherus Oncology, Inc.#

1 labor condition applications certified in fiscal 2025 for 1 positions, at a median wage of $150 K a year.

Certified, FY2025
1
#2,043 among companies on value.today
Worker positions
1
Median wage offered
$150 K
a year, full-time
Applications filed
1
Coherus Oncology, Inc.: most frequent H-1B job titles in fiscal 2025
Job titlePositionsMedian wage offered
Senior Scientist, Translational MedicineMolecular and Cellular Biologists1$150 K

Where: Camarillo, CA 1

Coherus Oncology, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202511$150 K1
FY202411$115 K1
FY202266$153 K6
FY202044$105 K4

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Coherus BioSciences, Inc.

Layoffs at Coherus Oncology, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
51
2017–2023
Latest
—
2023-03-02
Coherus Oncology, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2023············—
2017·····51······51
Coherus Oncology, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
Not statedRestructuring planSEC 8-KCompany-wide planFiling
51 peopleRestructuring planSEC 8-K“Under this plan, the Company reduced its workforce by 51 employees (approximately 30%).”Filing

Source: State WARN notices and SEC 8-K item 2.05

How Coherus Oncology, Inc. compares in Biotechnology

  • Revenue$42 M · higher than 57% of 647
  • Net margin-253.4% · higher than 22% of 408
  • Revenue growth59.8% · higher than 75% of 438

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Coherus Oncology, Inc.🇺🇸——-253.4%+59.8%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 16, 2026

Figures from SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Coherus Oncology, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Coherus Oncology, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Coherus Oncology, Inc.? Suggest a correction